In the bevacizumab group, patients carrying the ENOS-rs1799983-TT genotype, leading to a reduced NO production, had higher severe toxicity, particular grade 3-4 hypertension and proteinuria (GG+GT: 8% vs. TT: 50%; p = 0.0002) [41]. The gene discussed is NOS3; the disease is hypertensive disorder.